Inhibrx Historical Financial Ratios

INBX Stock  USD 15.26  0.37  2.37%   
Inhibrx is lately reporting on over 99 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 43.23 or Days Sales Outstanding of 166 will help investors to properly organize and evaluate Inhibrx financial condition quickly.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibrx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
For more information on how to buy Inhibrx Stock please use our How to Invest in Inhibrx guide.

About Inhibrx Financial Ratios Analysis

InhibrxFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Inhibrx investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Inhibrx financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Inhibrx history.

Inhibrx Financial Ratios Chart

At this time, Inhibrx's Capex To Revenue is fairly stable compared to the past year. Cash Per Share is likely to rise to 6.19 in 2024, whereas Free Cash Flow Yield is likely to drop (0.12) in 2024.
Add Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Inhibrx stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Inhibrx sales, a figure that is much harder to manipulate than other Inhibrx multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Dividend Yield

Dividend Yield is Inhibrx dividend as a percentage of Inhibrx stock price. Inhibrx dividend yield is a measure of Inhibrx stock productivity, which can be interpreted as interest rate earned on an Inhibrx investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.
Most ratios from Inhibrx's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Inhibrx current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibrx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
For more information on how to buy Inhibrx Stock please use our How to Invest in Inhibrx guide.At this time, Inhibrx's Capex To Revenue is fairly stable compared to the past year. Cash Per Share is likely to rise to 6.19 in 2024, whereas Free Cash Flow Yield is likely to drop (0.12) in 2024.
 2023 2024 (projected)
Dividend Yield0.0017050.002089
Price To Sales Ratio994.971.0K

Inhibrx fundamentals Correlations

-0.180.650.970.33-0.87-0.910.690.651.0-0.91-0.29-0.6-0.86-0.94-0.490.970.760.690.310.520.130.680.96-0.34-0.95
-0.18-0.78-0.07-0.120.530.51-0.1-0.78-0.170.51-0.280.80.590.150.85-0.15-0.52-0.780.24-0.920.29-0.79-0.270.840.42
0.65-0.780.580.3-0.83-0.860.61.00.64-0.860.23-0.9-0.9-0.62-0.970.630.790.97-0.010.92-0.320.970.73-0.9-0.82
0.97-0.070.580.26-0.76-0.840.770.580.98-0.84-0.27-0.47-0.78-0.97-0.420.990.640.590.240.430.060.580.96-0.27-0.9
0.33-0.120.30.26-0.41-0.51-0.060.30.32-0.5-0.62-0.54-0.48-0.33-0.170.220.710.340.420.190.580.310.35-0.06-0.48
-0.870.53-0.83-0.76-0.410.96-0.56-0.83-0.860.960.090.860.960.760.76-0.79-0.92-0.92-0.27-0.76-0.01-0.91-0.810.640.93
-0.910.51-0.86-0.84-0.510.96-0.6-0.86-0.911.00.20.860.990.850.74-0.86-0.93-0.9-0.26-0.76-0.07-0.89-0.920.60.99
0.69-0.10.60.77-0.06-0.56-0.60.60.7-0.610.33-0.27-0.62-0.79-0.540.820.370.540.130.39-0.550.560.7-0.53-0.65
0.65-0.781.00.580.3-0.83-0.860.60.64-0.860.23-0.9-0.9-0.62-0.970.630.790.97-0.010.92-0.320.970.73-0.9-0.82
1.0-0.170.640.980.32-0.86-0.910.70.64-0.91-0.29-0.59-0.86-0.94-0.490.970.760.690.310.510.130.670.96-0.33-0.95
-0.910.51-0.86-0.84-0.50.961.0-0.61-0.86-0.910.190.860.990.860.75-0.86-0.93-0.9-0.26-0.76-0.06-0.89-0.920.610.99
-0.29-0.280.23-0.27-0.620.090.20.330.23-0.290.190.080.110.26-0.39-0.18-0.290.14-0.290.17-0.930.18-0.26-0.560.23
-0.60.8-0.9-0.47-0.540.860.86-0.27-0.9-0.590.860.080.890.50.86-0.5-0.91-0.94-0.07-0.89-0.05-0.93-0.640.750.8
-0.860.59-0.9-0.78-0.480.960.99-0.62-0.9-0.860.990.110.890.830.8-0.83-0.93-0.94-0.27-0.820.03-0.93-0.860.70.97
-0.940.15-0.62-0.97-0.330.760.85-0.79-0.62-0.940.860.260.50.830.47-0.99-0.68-0.64-0.34-0.50.0-0.63-0.930.350.9
-0.490.85-0.97-0.42-0.170.760.74-0.54-0.97-0.490.75-0.390.860.80.47-0.49-0.69-0.940.12-0.930.46-0.95-0.570.970.69
0.97-0.150.630.990.22-0.79-0.860.820.630.97-0.86-0.18-0.5-0.83-0.99-0.490.660.650.290.51-0.040.650.94-0.37-0.91
0.76-0.520.790.640.71-0.92-0.930.370.790.76-0.93-0.29-0.91-0.93-0.68-0.690.660.870.360.710.220.850.74-0.56-0.9
0.69-0.780.970.590.34-0.92-0.90.540.970.69-0.90.14-0.94-0.94-0.64-0.940.650.870.090.93-0.221.00.71-0.87-0.85
0.310.24-0.010.240.42-0.27-0.260.13-0.010.31-0.26-0.29-0.07-0.27-0.340.120.290.360.09-0.110.280.080.180.09-0.28
0.52-0.920.920.430.19-0.76-0.760.390.920.51-0.760.17-0.89-0.82-0.5-0.930.510.710.93-0.11-0.260.930.59-0.87-0.7
0.130.29-0.320.060.58-0.01-0.07-0.55-0.320.13-0.06-0.93-0.050.030.00.46-0.040.22-0.220.28-0.26-0.260.090.61-0.08
0.68-0.790.970.580.31-0.91-0.890.560.970.67-0.890.18-0.93-0.93-0.63-0.950.650.851.00.080.93-0.260.7-0.89-0.84
0.96-0.270.730.960.35-0.81-0.920.70.730.96-0.92-0.26-0.64-0.86-0.93-0.570.940.740.710.180.590.090.7-0.41-0.95
-0.340.84-0.9-0.27-0.060.640.6-0.53-0.9-0.330.61-0.560.750.70.350.97-0.37-0.56-0.870.09-0.870.61-0.89-0.410.54
-0.950.42-0.82-0.9-0.480.930.99-0.65-0.82-0.950.990.230.80.970.90.69-0.91-0.9-0.85-0.28-0.7-0.08-0.84-0.950.54
Click cells to compare fundamentals

Inhibrx Account Relationship Matchups

Inhibrx fundamentals Accounts

201920202021202220232024 (projected)
Price To Sales Ratio82.9365.03232.97453.75994.971.0K
Ptb Ratio(8.06)11.0431.6917.0241.1743.23
Days Sales Outstanding17.5817.5344.9843.07157.76165.65
Book Value Per Share(2.56)2.991.381.450.920.97
Free Cash Flow Yield(0.0439)(0.0449)(0.0592)(0.0489)(0.12)(0.11)
Operating Cash Flow Per Share(0.88)(1.9)(2.11)(2.87)(4.1)(3.9)
Stock Based Compensation To Revenue0.440.392.118.1713.814.49
Capex To Depreciation1.561.340.720.563.864.05
Pb Ratio(8.06)11.0431.6917.0241.1743.23
Ev To Sales86.2557.9224.43420.78957.311.0K
Free Cash Flow Per Share(0.93)(1.95)(2.14)(2.89)(4.2)(3.99)
Roic0.86(0.6)(0.61)(0.49)(0.87)(0.82)
Inventory Turnover14.94(0.57)(3.06)(11.07)(0.1)(0.0976)
Net Income Per Share(1.41)(2.99)(2.15)(3.62)(5.12)(4.87)
Days Of Inventory On Hand24.43(642.04)(119.22)(32.96)(3.6K)(3.4K)
Payables Turnover5.1215.385.460.290.660.14
Sales General And Administrative To Revenue0.990.531.739.716.3217.14
Research And Ddevelopement To Revenue5.275.7410.0350.59106.47111.79
Capex To Revenue0.20.110.120.312.552.68
Cash Per Share0.325.093.456.835.96.19
Pocfratio(23.51)(17.36)(20.67)(8.57)(9.26)(9.73)
Interest Coverage(7.64)(6.24)(14.68)(8.02)(6.89)(7.23)
Capex To Operating Cash Flow(0.0564)(0.0284)(0.0108)(0.00595)(0.0238)(0.0249)
Pfcf Ratio(22.25)(16.88)(20.45)(8.52)(9.05)(9.5)
Days Payables Outstanding23.7366.841.2K556.992.5K2.7K
Income Quality0.620.630.980.790.81.05
Roe0.55(1.0)(1.56)(2.5)(5.55)(5.27)
Ev To Operating Cash Flow(24.45)(15.46)(19.91)(7.95)(8.91)(9.36)
Pe Ratio(14.67)(11.01)(20.3)(6.8)(7.42)(7.79)
Return On Tangible Assets(1.94)(0.53)(0.54)(0.5)(0.78)(0.82)
Ev To Free Cash Flow(23.14)(15.03)(19.7)(7.9)(8.71)(9.14)
Earnings Yield(0.0682)(0.0908)(0.0493)(0.15)(0.13)(0.14)
Net Debt To E B I T D A(0.71)1.350.790.570.330.21
Current Ratio0.764.216.210.175.253.26
Tangible Book Value Per Share(2.56)2.991.381.450.920.97
Receivables Turnover20.7620.838.128.472.312.2
Graham Number9.014.198.1710.8610.316.5
Shareholders Equity Per Share(2.56)2.991.381.450.920.97
Debt To Equity(0.45)0.51.383.514.85.05
Capex Per Share0.04950.0540.02270.01710.09750.1

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Inhibrx Stock Analysis

When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.